Ethical and Scientific Issues in Studying the Safety of Approved Drugs
Afbeeldingen
Artikel vergelijken
Co-auteur:
Onbekend
Institute Of Medicine
- Engels
- Paperback
- 9780309218139
- 30 augustus 2012
- 275 pagina's
Samenvatting
An estimated 48 percent of the population takes at least one prescription drug in a given month. Drugs provide great benefits to society by saving or improving lives. Many drugs are also associated with side effects or adverse events, some serious and some discovered only after the drug is on the market. The discovery of new adverse events in the postmarketing setting is part of the normal natural history of approved drugs, and timely identification and warning about drug risks are central to the mission of the Food and Drug Administration (FDA). Not all risks associated with a drug are known at the time of approval, because safety data are collected from studies that involve a relatively small number of human subjects during a relatively short period. Written in response to a request by the FDA, Ethical and Scientific Issues in Studying the Safety of Approved Drugs discusses ethical and informed consent issues in conducting studies in the postmarketing setting. It evaluates the strengths and weaknesses of various approaches to generate evidence about safety questions, and makes recommendations for appropriate followup studies and randomized clinical trials. The book provides guidance to the FDA on how it should factor in different kinds of evidence in its regulatory decisions. Ethical and Scientific Issues in Studying the Safety of Approved Drugs will be of interest to the pharmaceutical industry, patient advocates, researchers, and consumer groups. Table of Contents Front Matter Abstract Summary 1 Introduction 2 Incorporating Benefit and Risk Assessment and BenefitRisk Management into Food and Drug Administration Decision-Making 3 Evidence and Decision-Making 4 Selection and Oversight of Required Postmarketing Studies 5 Synthesis Appendix A: Other Elements of the Food and Drug Administration Amendments Act Appendix B: Committee's Letter Report Appendix C: Open Session Agendas Appendix D: Decision Conferencing and Multicriteria Decision Analysis Appendix E: Benefit and Risk Assessment and Management Plan Document Template Appendix F: Committee Biosketches
Productspecificaties
Wij vonden geen specificaties voor jouw zoekopdracht '{SEARCH}'.
Inhoud
- Taal
- en
- Bindwijze
- Paperback
- Oorspronkelijke releasedatum
- 30 augustus 2012
- Aantal pagina's
- 275
- Illustraties
- Nee
Betrokkenen
- Hoofdauteur
- Institute Of Medicine
- Tweede Auteur
- Board on Population Health and Public Health Practice
- Co Auteur
- Institute Of Medicine
- Hoofduitgeverij
- National Academies Press
Overige kenmerken
- Editie
- 1
- Extra groot lettertype
- Nee
- Studieboek
- Nee
- Verpakking breedte
- 152 mm
- Verpakking hoogte
- 229 mm
- Verpakking lengte
- 229 mm
- Verpakkingsgewicht
- 499 g
EAN
- EAN
- 9780309218139
Je vindt dit artikel in
- Categorieën
- Beschikbaarheid
- Leverbaar
- Taal
- Engels
- Boek, ebook of luisterboek?
- Boek
- Studieboek of algemeen
- Studieboeken
Kies gewenste uitvoering
Bindwijze
: Paperback
Prijsinformatie en bestellen
De prijs van dit product is 56 euro en 99 cent.
3 weken
Verkoop door bol
- Prijs inclusief verzendkosten, verstuurd door bol
- Ophalen bij een bol afhaalpunt mogelijk
- 30 dagen bedenktijd en gratis retourneren
- Dag en nacht klantenservice
Rapporteer dit artikel
Je wilt melding doen van illegale inhoud over dit artikel:
- Ik wil melding doen als klant
- Ik wil melding doen als autoriteit of trusted flagger
- Ik wil melding doen als partner
- Ik wil melding doen als merkhouder
Geen klant, autoriteit, trusted flagger, merkhouder of partner? Gebruik dan onderstaande link om melding te doen.